DDInter1676 DDInter1081
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or
Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Lithium carbonate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxycycline
Lithium carbonate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Lithium carbonate {u} may lead to a major life threatening interaction when taken with {v} Cisapride
Lithium carbonate {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Lithium carbonate may cause a minor interaction that can limit clinical effects when taken with Doxycycline
Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Lithium carbonate may lead to a major life threatening interaction when taken with Cisapride
Lithium carbonate may lead to a major life threatening interaction when taken with Ivosidenib